Comparison Between 18F-Florapronol and 18F-Florbetaben Imaging in Patients With Cognitive Impairment

키워드

참고문헌 (35)

1. DeTure MA, "The neuropathological diagnosis of Alzheimer’s disease", Mol Neurodegener, 14, pp.32~ (2019)
2. Blennow K, "Amyloid biomarkers in Alzheimer’s disease", Trends Pharmacol Sci, 36, pp.297~309 (2015)
3. Lowe VJ, "An autoradiographic evaluation of AV-1451 Tau PET in dementia", Acta Neuropathol Commun, 4, pp.58~ (2016)
4. Brier MR, "Tau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease", Sci Transl Med, 8, pp.338~ (2016)
5. Jack CR Jr, "NIA-AA research framework : toward a biological definition of Alzheimer’s disease", Alzheimers Dement, 14, pp.535~562 (2018)
6. Hardy JA, "Alzheimer’s disease : the amyloid cascade hypothesis", Science, 256, pp.184~185 (1992)
7. Jack CR Jr, "Tracking pathophysiological processes in Alzheimer’s disease : an updated hypothetical model of dynamic biomarkers", Lancet Neurol, 12, pp.207~216 (2013)
8. Klunk WE, "Imaging brain amyloid in Alzheimer’s disease with Pittsburgh compound-B", Ann Neurol, 55, pp.306~319 (2004)
9. Driscoll I, "Correspondence between in vivo 11C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques", Acta Neuropathol, 124, pp.823~831 (2012)
10. Ikonomovic MD, "Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer’s disease", Brain, 131(Pt 6), pp.1630~1645 (2008)
11. Morris E, "Diagnostic accuracy of 18F amyloid PET tracers for the diagnosis of Alzheimer’s disease : a systematic review and meta-analysis", Eur J Nucl Med Mol Imaging, 43, pp.374~385 (2016)
12. Sabri O, "Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer’s disease : phase 3 study", Alzheimers Dement, 11, pp.964~974 (2015)
13. Curtis C, "Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density", JAMA Neurol, 72, pp.287~294 (2015)
14. Oh SJ, "Early detection of Aβ deposition in the 5xFAD mouse by amyloid PET", Contrast Media Mol Imaging, 2018, pp.5272014~ (2018)
15. Byun BH, "Head-tohead comparison of 11C-PiB and 18F-FC119S for Aβ imaging in healthy subjects, mild cognitive impairment patients, and Alzheimer’s disease patients", Medicine(Baltimore), 96, pp.e6441~ (2017)
16. McKhann GM, "The diagnosis of dementia due to Alzheimer’s disease : recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease", Alzheimers Dement, 7, pp.263~269 (2011)
17. Albert MS, "The diagnosis of mild cognitive impairment due to Alzheimer’s disease : recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease", Alzheimers Dement, 7, pp.270~279 (2011)
18. Ye BS, "Distinguishing between dementia with Lewy bodies and Alzheimer’s disease using metabolic patterns", Neurobiol Aging, 87, pp.11~17 (2020)
19. Fonov V, "Atrophy specific MRI brain template for Alzheimer’s disease and mild cognitive impairment", Proceedings of the Alzheimer’s Association International Conference, pp.S58~ (2011), AAIC
20. Kim JS, "Automated 3-D extraction and evaluation of the inner and outer cortical surfaces using a Laplacian map and partial volume effect classification", Neuroimage, 27, pp.210~221 (2005)
21. Funck T, "Surface-based partial-volume correction for high-resolution PET", Neuroimage, 102(Pt 2), pp.674~687 (2014)
22. Lee YG, "Amyloid-β-related and unrelated cortical thinning in dementia with Lewy bodies", Neurobiol Aging, 72, pp.32~39 (2018)
23. Youden WJ, "Index for rating diagnostic tests", Cancer, 3, pp.32~35 (1950)
24. McKeith IG, "Diagnosis and management of dementia with Lewy bodies : fourth consensus report of the DLB consortium", Neurology, 89, pp.88~100 (2017)
25. Lee JH, "Identification of pure subcortical vascular dementia using 11C-Pittsburgh compound B", Neurology, 77, pp.18~25 (2011)
26. Ye BS, "Longitudinal outcomes of amyloid positive versus negative amnestic mild cognitive impairments : a three-year longitudinal study", Sci Rep, 8, pp.5557~ (2018)
27. Dickson TC, "The morphological phenotype of beta-amyloid plaques and associated neuritic changes in Alzheimer’s disease", Neuroscience, 105, pp.99~107 (2001)
28. Sabri O, "Impact of morphologically distinct amyloid β(Aβ)deposits on 18F-florbetaben(FBB)PET scans", J Nucl Med, 56(supplement 3), pp.195~ (2015)
29. Cho H, "In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum", Ann Neurol, 80, pp.247~258 (2016)
30. Harrison TM, "Distinct effects of beta-amyloid and tau on cortical thickness in cognitively healthy older adults", Alzheimers Dement, 17, pp.1085~1096 (2021)
31. Ossenkoppele R, "Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease", Neurology, 92, pp.e601~e612 (2019)
32. Braak H, "Neuropathological stageing of Alzheimer-related changes", Acta Neuropathol, 82, pp.239~259 (1991)
33. Kantarci K, "AV-1451 tau and β-amyloid positron emission tomography imaging in dementia with Lewy bodies", Ann Neurol, 81, pp.58~67 (2017)
34. Gomperts SN, "Tau positron emission tomographic imaging in the Lewy body diseases", JAMA Neurol, 73, pp.1334~1341 (2016)
35. Obi K, "Relationship of phosphorylated alpha-synuclein and tau accumulation to Aβ deposition in the cerebral cortex of dementia with Lewy bodies", Exp Neurol, 210, pp.409~420 (2008)

관련 논문AI추천